Finerenone Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Finerenone comprises 196 peer-reviewed publications across 15 journals, 3 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Heart Failure, Renal Insufficiency, Chronic, Hematuria, Benign Familial, and Diabetes Mellitus, Type 2. Most recent publication: Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes: An analysis from FIDELITY., J Diabetes Complications, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Why Has it Been Challenging to Modify Kidney Disease Progression in Patients With Heart Failure?
    Vaduganathan M, Neuen BL, McCausland F, et al. · J Am Coll Cardiol · 2024
    PubMed: PMID 39217561 · NCT04435626 (FINEARTS-HF) · Heart Failure
  2. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.
    Vaduganathan M, Filippatos G, Claggett BL, et al. · Nat Med · 2024
    PubMed: PMID 39218030 · NCT04435626 (FINEARTS-HF) · Heart Failure
  3. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
    Solomon SD, McMurray JJV, Vaduganathan M, et al. · N Engl J Med · 2024
    PubMed: PMID 39225278 · NCT04435626 (FINEARTS-HF) · Heart Failure
  4. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
    Pitt B, Filippatos G, Agarwal R, et al. · N Engl J Med · 2021
    PubMed: PMID 34449181 · NCT02545049 (FIGARO-DKD) · Diabetes Mellitus, Type 2
  5. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis.
    Jhund PS, Talebi A, Henderson AD, et al. · Lancet · 2024
    PubMed: PMID 39232490 · NCT04435626 (FINEARTS-HF) · Heart Failure
  6. SGLT2-Inhibition in Patients With Alport Syndrome.
    Boeckhaus J, Gale DP, Simon J, et al. · Kidney Int Rep · 2025
    PubMed: PMID 39698346 · NCT02378805 (Alport-XXL) · Hematuria, Benign Familial
  7. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
    Bakris GL, Agarwal R, Chan JC, et al. · JAMA · 2015
    PubMed: PMID 26325557 · NCT01874431 (ARTS-DN) · Diabetic Nephropathies
  8. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
    Bakris GL, Agarwal R, Anker SD, et al. · N Engl J Med · 2020
    PubMed: PMID 33264825 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT02540993
FIDELIO-DKD
Renal Insufficiency, ChronicThe First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death
From randomization up until the first occurrence of the primary renal composite endpoint, or censoring at the end of the study, with an average follow-up time of 32 months
Finerenone504 Participants
Placebo600 Participants
NCT02545049
FIGARO-DKD
Diabetes Mellitus, Type 2The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non Fatal Stroke, or Hospitalization for Heart Failure.
From randomization up until the first occurrence of the CV composite endpoint, or censoring at the end of the study, with an average study duration of 41 months.
Finerenone458 Participants
Placebo519 Participants
NCT04435626
FINEARTS-HF
Heart FailureOccurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events
From randomization up until the end of study, with an average study duration of 32 months
Finerenone (BAY94-8862)624 Participants
Finerenone (BAY94-8862)1083 events
Finerenone (BAY94-8862)1083 events
Finerenone (BAY94-8862)624 Participants
Placebo719 Participants
Placebo1283 events
Placebo1283 events
Placebo719 Participants

Publications by year

1993–2026: 196 publications.

1993
1
1997
1
1999
1
2000
1
2002
2
2003
2
2004
2
2005
2
2007
2
2008
2
2009
2
2010
1
2011
2
2012
2
2013
3
2014
1
2015
5
2016
2
2017
4
2018
4
2019
8
2020
14
2021
18
2022
18
2023
16
2024
23
2025
30
2026
27

Publications by indication

Heart Failure (110)

  • Finerenone and NYHA Functional Class in Heart Failure: The FINEARTS-HF Trial.
    JACC Heart Fail · 2026 · PMID 40232214 · NCT04435626
  • Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial.
    JACC Heart Fail · 2026 · PMID 40208137 · NCT04435626
  • Finerenone according to insulin resistance in heart failure: Insights from the FINEARTS-HF trial.
    Eur J Heart Fail · 2026 · PMID 40916719 · NCT04435626
  • Biomarker, Functional Status, and Quality-of-Life Trajectories Before Modes of Death in Heart Failure: Post Hoc Analysis of the FINEARTS-HF Randomized Clinical Trial.
    JAMA Cardiol · 2026 · PMID 41903171 · NCT04435626
  • A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HF.
    Eur Heart J Cardiovasc Pharmacother · 2026 · PMID 41697954 · NCT04435626

Renal Insufficiency, Chronic (41)

  • Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes: An analysis from FIDELITY.
    J Diabetes Complications · 2026 · PMID 41679125 · NCT02540993
  • Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.
    J Am Soc Nephrol · 2026 · PMID 41196655 · NCT02540993
  • Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point.
    J Am Soc Nephrol · 2026 · PMID 40526444 · NCT02540993
  • Temporal Changes in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use in Patients with Chronic Kidney Disease and Type 2 Diabetes, 2012-2023: A US Cohort Study.
    Diabetes Ther · 2026 · PMID 41364416 · NCT05526157
  • Finerenone in Type 1 Diabetes and Chronic Kidney Disease.
    N Engl J Med · 2026 · PMID 41780000 · NCT05901831

Hematuria, Benign Familial (11)

  • SGLT2-Inhibition in Patients With Alport Syndrome.
    Kidney Int Rep · 2025 · PMID 39698346 · NCT02378805
  • Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome.
    Pediatr Nephrol · 2022 · PMID 33772369 · NCT02378805
  • Lifelong effect of therapy in young patients with the COL4A5 Alport missense variant p.(Gly624Asp): a prospective cohort study.
    Nephrol Dial Transplant · 2022 · PMID 35022790 · NCT02378805
  • Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Hereditary Podocytopathies, Alport Syndrome, and FSGS: A Case Series to Better Plan a Large-Scale Study.
    Cells · 2021 · PMID 34359984 · NCT02378805
  • Clinical trial recommendations for potential Alport syndrome therapies.
    Kidney Int · 2021 · PMID 32386680 · NCT02378805

Diabetes Mellitus, Type 2 (11)

  • Finerenone Efficacy in Patients with Chronic Kidney Disease, Type 2 Diabetes, and Anemia in FIDELITY.
    JACC Adv · 2026 · PMID 40021271 · NCT02545049
  • Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy.
    Clin J Am Soc Nephrol · 2026 · PMID 41533467 · NCT02545049
  • An integrative framework for drug target discovery bridging clinical trial and genetic data insights.
    J Transl Med · 2026 · PMID 41827014 · NCT02545049
  • Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index: FIDELITY Post Hoc Analysis.
    Clin J Am Soc Nephrol · 2025 · PMID 40315020 · NCT02545049
  • Protocol for the FibroCAN study: a randomised controlled trial of finerenone treatment for early-stage cardiovascular autonomic neuropathy in type 2 diabetes.
    BMJ Open · 2025 · PMID 41130701 · NCT06906081

Hyperaldosteronism (11)

  • Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism: A Multicenter Prospective Study.
    Hypertension · 2026 · PMID 41568520 · NCT06381323
  • 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).
    J Hypertens · 2023 · PMID 37345492 · NCT06457074
  • Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension.
    J Hypertens · 2021 · PMID 32890264 · NCT06457074
  • Diagnosis of Primary Aldosteronism by Seated Saline Suppression Test-Variability Between Immunoassay and HPLC-MS/MS.
    J Clin Endocrinol Metab · 2020 · PMID 31676899 · NCT06457074
  • Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association.
    Hypertension · 2019 · PMID 30827125 · NCT06457074

Diabetic Nephropathies (6)

  • Effect of Finerenone on Morbidity and Mortality in CKD.
    J Am Soc Nephrol · 2026 · PMID 40938666 · NCT01874431
  • Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes.
    J Hypertens · 2023 · PMID 36583355 · NCT01874431
  • Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease.
    Clin Pharmacokinet · 2021 · PMID 31583611 · NCT01874431
  • Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment.
    Eur J Drug Metab Pharmacokinet · 2020 · PMID 30825073 · NCT04881994
  • Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
    Cochrane Database Syst Rev · 2020 · PMID 33107592 · NCT01874431

Publications by journal

Trial-results highlights

Clinical trials have investigated finerenone for conditions including chronic renal insufficiency and type 2 diabetes. In the NCT02540993 (FIDELIO-DKD) study, which focused on chronic renal insufficiency with an average follow-up of 32 months, 504 participants were in the finerenone arm and 600 participants were in the placebo arm. The primary endpoint for this study was the first occurrence of a composite endpoint, which included the onset of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death. Another study, NCT02545049 (FIGARO-DKD), investigated type 2 diabetes over an average study duration of 41 months. In this trial, 458 participants received finerenone, while 519 participants received placebo. The primary endpoint for NCT02545049 was the first occurrence of a composite endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure.

For heart failure, the NCT04435626 (FINEARTS-HF) study assessed finerenone over an average study duration of 32 months. The primary endpoint was the occurrence of a composite endpoint of cardiovascular death and total (first and recurrent) heart failure events. In the finerenone arm of NCT04435626, there were 624 participants and 1083 events. The placebo arm of NCT04435626 included 719 participants and reported 1283 events.

All values presented are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Finerenone publications (196)

2026 (27 papers)

  1. Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes: An analysis from FIDELITY.
    Weingold R, Filippatos G, Anker SD, et al. · J Diabetes Complications · 2026 · Derived
    PubMed: PMID 41679125 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  2. Finerenone Efficacy in Patients with Chronic Kidney Disease, Type 2 Diabetes, and Anemia in FIDELITY.
    Singh AK, James G, Anker SD, et al. · JACC Adv · 2026 · Derived
    PubMed: PMID 40021271 · NCT02545049 (FIGARO-DKD) · Diabetes Mellitus, Type 2
  3. Finerenone and NYHA Functional Class in Heart Failure: The FINEARTS-HF Trial.
    Ostrominski JW, Vaduganathan M, Claggett BL, et al. · JACC Heart Fail · 2026 · Derived
    PubMed: PMID 40232214 · NCT04435626 (FINEARTS-HF) · Heart Failure
  4. Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial.
    Ostrominski JW, Mc Causland FR, Claggett BL, et al. · JACC Heart Fail · 2026 · Derived
    PubMed: PMID 40208137 · NCT04435626 (FINEARTS-HF) · Heart Failure
  5. Effect of Finerenone on Morbidity and Mortality in CKD.
    Ostrominski JW, Filippatos G, Claggett BL, et al. · J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 40938666 · NCT01874431 (ARTS-DN) · Diabetic Nephropathies
  6. Finerenone according to insulin resistance in heart failure: Insights from the FINEARTS-HF trial.
    Ostrominski JW, Claggett BL, Desai AS, et al. · Eur J Heart Fail · 2026 · Derived
    PubMed: PMID 40916719 · NCT04435626 (FINEARTS-HF) · Heart Failure
  7. Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy.
    Munoz Mendoza J, Weir MR, Anker SD, et al. · Clin J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 41533467 · NCT02545049 (FIGARO-DKD) · Diabetes Mellitus, Type 2
  8. Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.
    Mottl A, Scott C, Green JB, et al. · J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 41196655 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  9. An integrative framework for drug target discovery bridging clinical trial and genetic data insights.
    Mielke J, Strunz T, Lee J, et al. · J Transl Med · 2026 · Derived
    PubMed: PMID 41827014 · NCT02545049 (FIGARO-DKD) · Diabetes Mellitus, Type 2
  10. Biomarker, Functional Status, and Quality-of-Life Trajectories Before Modes of Death in Heart Failure: Post Hoc Analysis of the FINEARTS-HF Randomized Clinical Trial.
    Lu H, Kosztin A, Claggett BL, et al. · JAMA Cardiol · 2026 · Derived
    PubMed: PMID 41903171 · NCT04435626 (FINEARTS-HF) · Heart Failure
  11. Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism: A Multicenter Prospective Study.
    Li P, Yang F, Lou Y, et al. · Hypertension · 2026 · Derived
    PubMed: PMID 41568520 · NCT06381323 · Hyperaldosteronism
  12. Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point.
    Jongs N, Gasparyan SB, Frison L, et al. · J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 40526444 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  13. Temporal Changes in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use in Patients with Chronic Kidney Disease and Type 2 Diabetes, 2012-2023: A US Cohort Study.
    Johannes CB, Coleman CI, Kovesdy CP, et al. · Diabetes Ther · 2026 · Derived
    PubMed: PMID 41364416 · NCT05526157 (FINEGUST) · Renal Insufficiency, Chronic
  14. A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HF.
    Henderson AD, Docherty KF, Talebi A, et al. · Eur Heart J Cardiovasc Pharmacother · 2026 · Derived
    PubMed: PMID 41697954 · NCT04435626 (FINEARTS-HF) · Heart Failure
  15. Finerenone in Type 1 Diabetes and Chronic Kidney Disease.
    Heerspink HJL, Birkenfeld AL, Cherney DZI, et al. · N Engl J Med · 2026 · Derived
    PubMed: PMID 41780000 · NCT05901831 (FINE-ONE) · Renal Insufficiency, Chronic
  16. Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire.
    Hamatani Y, Peikert A, Claggett BL, et al. · Eur J Heart Fail · 2026 · Derived
    PubMed: PMID 41817207 · NCT04435626 (FINEARTS-HF) · Heart Failure
  17. Interchangeability of the KCCQ-12 and KCCQ-23 Across >18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure.
    Hamatani Y, Claggett BL, Desai AS, et al. · J Am Coll Cardiol · 2026 · Derived
    PubMed: PMID 41995644 · NCT04435626 (FINEARTS-HF) · Heart Failure
  18. Finerenone-Related Risk of Hypotension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
    Foà A, Vaduganathan M, Claggett BL, et al. · JACC Heart Fail · 2026 · Derived
    PubMed: PMID 41364043 · NCT04435626 (FINEARTS-HF) · Heart Failure
  19. Albuminuria Is the Key Driver of Kidney Benefit with Aldosterone Receptor Antagonists in Type 2 Diabetes.
    Ferreira JP, Mendonça L, Marques P, et al. · J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 40892478 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  20. Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.
    Chimura M, Yang M, Henderson AD, et al. · Eur J Heart Fail · 2026 · Derived
    PubMed: PMID 40377177 · NCT04435626 (FINEARTS-HF) · Heart Failure
  21. EMPEROR-Preserved Risk Model and Outcomes in the FINEARTS-HF Trial: A Prespecified Secondary Analysis of FINEARTS-HF.
    Chimura M, McDowell K, Jhund PS, et al. · JAMA Cardiol · 2026 · Derived
    PubMed: PMID 41903165 · NCT04435626 (FINEARTS-HF) · Heart Failure
  22. Efficacy of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of heart rate and heart rhythm in the FINEARTS-HF trial.
    Chimura M, Jhund PS, Henderson AD, et al. · Eur J Heart Fail · 2026 · Derived
    PubMed: PMID 41771075 · NCT04435626 (FINEARTS-HF) · Heart Failure
  23. Efficacy and Safety of the Kidney Function-Based Finerenone Dosing Strategy Used in FINEARTS-HF.
    Chimura M, Henderson AD, Jhund PS, et al. · JACC Heart Fail · 2026 · Derived
    PubMed: PMID 41642173 · NCT04435626 (FINEARTS-HF) · Heart Failure
  24. Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF.
    Butt JH, Henderson AD, Jhund PS, et al. · Circ Heart Fail · 2026 · Derived
    PubMed: PMID 41608790 · NCT04435626 (FINEARTS-HF) · Heart Failure
  25. Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial.
    Agarwal R, Green JB, Heerspink HJL, et al. · J Am Coll Cardiol · 2026 · Derived
    PubMed: PMID 41493296 · NCT05254002 (CONFIDENCE) · Renal Insufficiency, Chronic
  26. Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia: Pre-Specified Analysis of CONFIDENCE.
    Agarwal R, Green JB, Heerspink HJL, et al. · Clin J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 40965042 · NCT05254002 (CONFIDENCE) · Renal Insufficiency, Chronic
  27. Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone.
    Agarwal R, Correa-Rotter R, Navaneethan SD, et al. · J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 41905767 · NCT05254002 (CONFIDENCE) · Renal Insufficiency, Chronic

2025 (30 papers)

  1. SGLT2-Inhibition in Patients With Alport Syndrome.
    Boeckhaus J, Gale DP, Simon J, et al. · Kidney Int Rep · 2025 · Trial result
    PubMed: PMID 39698346 · NCT02378805 (Alport-XXL) · Hematuria, Benign Familial
  2. Efficacy and safety of finerenone in IgA nephropathy: an observational multicentre study.
    Wang QR, Wu L, Huang J, et al. · Clin Kidney J · 2025 · Derived
    PubMed: PMID 40357496 · NCT06460987 · Proteinuria
  3. Late Allograft Loss and Contemporary Cardiorenal Metabolic Therapies.
    Vinson AJ, Matas A · J Am Soc Nephrol · 2025 · Derived
    PubMed: PMID 40193211 · NCT06059664 · Heart Failure
  4. Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
    Vardeny O, Vaduganathan M, Claggett BL, et al. · JAMA Cardiol · 2025 · Derived
    PubMed: PMID 39550716 · NCT04435626 (FINEARTS-HF) · Heart Failure
  5. Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial.
    Vaduganathan M, Green JB, Heerspink HJL, et al. · Nephrol Dial Transplant · 2025 · Derived
    PubMed: PMID 40886054 · NCT05254002 (CONFIDENCE) · Renal Insufficiency, Chronic
  6. Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure.
    Vaduganathan M, Claggett BL, Kulac IJ, et al. · Circulation · 2025 · Derived
    PubMed: PMID 39340828 · NCT04435626 (FINEARTS-HF) · Heart Failure
  7. Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.
    Vaduganathan M, Claggett BL, Desai AS, et al. · JAMA Cardiol · 2025 · Derived
    PubMed: PMID 39332395 · NCT04435626 (FINEARTS-HF) · Heart Failure
  8. Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index: FIDELITY Post Hoc Analysis.
    Rossing P, Birkenfeld AL, Fioretto P, et al. · Clin J Am Soc Nephrol · 2025 · Derived
    PubMed: PMID 40315020 · NCT02545049 (FIGARO-DKD) · Diabetes Mellitus, Type 2
  9. Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone-a FIDELITY analysis.
    Pitt B, Agarwal R, Anker SD, et al. · Eur Heart J Cardiovasc Pharmacother · 2025 · Derived
    PubMed: PMID 39380152 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  10. Finerenone in Heart Failure With Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial.
    Pabon MA, Vardeny O, Vaduganathan M, et al. · JAMA Cardiol · 2025 · Derived
    PubMed: PMID 40397470 · NCT04435626 (FINEARTS-HF) · Heart Failure
  11. Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF.
    McDowell K, Docherty KF, Campbell RT, et al. · JAMA Cardiol · 2025 · Derived
    PubMed: PMID 40042880 · NCT04435626 (FINEARTS-HF) · Heart Failure
  12. Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF Trial.
    Mc Causland FR, Vaduganathan M, Claggett BL, et al. · J Am Coll Cardiol · 2025 · Derived
    PubMed: PMID 39490700 · NCT04435626 (FINEARTS-HF) · Heart Failure
  13. Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.
    Matsumoto S, Henderson AD, Jhund PS, et al. · JAMA Cardiol · 2025 · Derived
    PubMed: PMID 40156827 · NCT04435626 (FINEARTS-HF) · Heart Failure
  14. Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
    Lu H, Claggett BL, Vaduganathan M, et al. · JACC Heart Fail · 2025 · Derived
    PubMed: PMID 40857999 · NCT04435626 (FINEARTS-HF) · Heart Failure
  15. Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney disease.
    Kugathasan L, Aronson Y, Sridhar VS, et al. · Expert Rev Clin Immunol · 2025 · Derived
    PubMed: PMID 40693871 · NCT05901831 (FINE-ONE) · Renal Insufficiency, Chronic
  16. The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HF.
    Kondo T, Jhund PS, Henderson AD, et al. · Eur J Heart Fail · 2025 · Derived
    PubMed: PMID 40300840 · NCT04435626 (FINEARTS-HF) · Heart Failure
  17. Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney function.
    Katayama S, Anker SD, Zhu D, et al. · J Diabetes Complications · 2025 · Derived
    PubMed: PMID 41289823 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  18. Screening for Undiagnosed Heart Failure: A Viewpoint.
    Ferreira JP, Zannad F · J Card Fail · 2025 · Derived
    PubMed: PMID 40414280 · NCT04435626 (FINEARTS-HF) · Heart Failure
  19. Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial.
    Desai AS, Jhund PS, Vaduganathan M, et al. · JAMA Cardiol · 2025 · Derived
    PubMed: PMID 40159247 · NCT04435626 (FINEARTS-HF) · Heart Failure
  20. Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.
    Cunningham JW, Chatur S, Claggett BL, et al. · JAMA Cardiol · 2025 · Derived
    PubMed: PMID 40009358 · NCT04435626 (FINEARTS-HF) · Heart Failure
  21. Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.
    Chimura M, Wang X, Jhund PS, et al. · JAMA Cardiol · 2025 · Derived
    PubMed: PMID 39550721 · NCT04435626 (FINEARTS-HF) · Heart Failure
  22. Efficacy and Tolerability of Finerenone According to the Use and Dosage of Diuretics: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial.
    Chimura M, Jhund PS, Henderson AD, et al. · JAMA Cardiol · 2025 · Derived
    PubMed: PMID 40802267 · NCT04435626 (FINEARTS-HF) · Heart Failure
  23. Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial.
    Butt JH, Jhund PS, Henderson AD, et al. · Lancet Diabetes Endocrinol · 2025 · Derived
    PubMed: PMID 39818225 · NCT04435626 (FINEARTS-HF) · Heart Failure
  24. Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.
    Butt JH, Jhund PS, Henderson AD, et al. · Eur J Heart Fail · 2025 · Derived
    PubMed: PMID 40222820 · NCT04435626 (FINEARTS-HF) · Heart Failure
  25. Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial.
    Butt JH, Jhund PS, Henderson AD, et al. · JAMA Cardiol · 2025 · Derived
    PubMed: PMID 40531488 · NCT04435626 (FINEARTS-HF) · Heart Failure
  26. Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF.
    Butt JH, Henderson AD, Jhund PS, et al. · J Am Coll Cardiol · 2025 · Derived
    PubMed: PMID 39665701 · NCT04435626 (FINEARTS-HF) · Heart Failure
  27. Protocol for the FibroCAN study: a randomised controlled trial of finerenone treatment for early-stage cardiovascular autonomic neuropathy in type 2 diabetes.
    Bitsch Poulsen M, Okdahl T, Buciek JH, et al. · BMJ Open · 2025 · Derived
    PubMed: PMID 41130701 · NCT06906081 (FibroCAN) · Diabetes Mellitus, Type 2
  28. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.
    Agarwal R, Green JB, Heerspink HJL, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 40470996 · NCT05254002 (CONFIDENCE) · Renal Insufficiency, Chronic
  29. COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.
    Agarwal R, Green JB, Heerspink HJL, et al. · Nephrol Dial Transplant · 2025 · Derived
    PubMed: PMID 39916475 · NCT05254002 (CONFIDENCE) · Renal Insufficiency, Chronic
  30. Increasing Left Ventricular Mass and Death in Men and Women Investigated With Echocardiography.
    Playford D, Strange G, Joseph M, et al. · J Am Heart Assoc · 2025 · Background
    PubMed: PMID 41378460 · NCT07270367 (FINE-MECH) · Heart Failure

2024 (23 papers)

  1. Why Has it Been Challenging to Modify Kidney Disease Progression in Patients With Heart Failure?
    Vaduganathan M, Neuen BL, McCausland F, et al. · J Am Coll Cardiol · 2024 · Trial result
    PubMed: PMID 39217561 · NCT04435626 (FINEARTS-HF) · Heart Failure
  2. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.
    Vaduganathan M, Filippatos G, Claggett BL, et al. · Nat Med · 2024 · Trial result
    PubMed: PMID 39218030 · NCT04435626 (FINEARTS-HF) · Heart Failure
  3. Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial.
    Vaduganathan M, Claggett BL, Lam CSP, et al. · Eur J Heart Fail · 2024 · Trial result
    PubMed: PMID 38742248 · NCT04435626 (FINEARTS-HF) · Heart Failure
  4. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial.
    Solomon SD, Ostrominski JW, Vaduganathan M, et al. · Eur J Heart Fail · 2024 · Trial result
    PubMed: PMID 38733212 · NCT04435626 (FINEARTS-HF) · Heart Failure
  5. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
    Solomon SD, McMurray JJV, Vaduganathan M, et al. · N Engl J Med · 2024 · Trial result
    PubMed: PMID 39225278 · NCT04435626 (FINEARTS-HF) · Heart Failure
  6. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials.
    Pamporis K, Karakasis P, Sagris M, et al. · Curr Probl Cardiol · 2024 · Trial result
    PubMed: PMID 38692445 · NCT07351864 (FIN-SGLT2-HF) · Heart Failure
  7. Cardiovascular-Kidney-Metabolic Overlap in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis.
    Ostrominski JW, Claggett BL, Miao ZM, et al. · J Am Coll Cardiol · 2024 · Trial result
    PubMed: PMID 38744407 · NCT04435626 (FINEARTS-HF) · Heart Failure
  8. Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart Failure.
    Ostrominski JW, Aggarwal R, Claggett BL, et al. · J Card Fail · 2024 · Trial result
    PubMed: PMID 38740173 · NCT04435626 (FINEARTS-HF) · Heart Failure
  9. Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF?
    Kondo T, Henderson AD, Docherty KF, et al. · J Am Coll Cardiol · 2024 · Trial result
    PubMed: PMID 39217560 · NCT04435626 (FINEARTS-HF) · Heart Failure
  10. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis.
    Jhund PS, Talebi A, Henderson AD, et al. · Lancet · 2024 · Trial result
    PubMed: PMID 39232490 · NCT04435626 (FINEARTS-HF) · Heart Failure
  11. Gamified Behavioral Science Intervention to Enhance Trial Enrollment: An Embedded Study Within the FINEARTS-HF Trial.
    Bhatt AS, Chatur S, Claggett BL, et al. · JACC Heart Fail · 2024 · Trial result
    PubMed: PMID 38944793 · NCT04435626 (FINEARTS-HF) · Heart Failure
  12. Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease.
    Zachariah T, Radhakrishnan J · Clin J Am Soc Nephrol · 2024 · Derived
    PubMed: PMID 39037799 · NCT05254002 (CONFIDENCE) · Renal Insufficiency, Chronic
  13. Interventions for BK virus infection in kidney transplant recipients.
    Wajih Z, Karpe KM, Walters GD, et al. · Cochrane Database Syst Rev · 2024 · Derived
    PubMed: PMID 39382091 · NCT06059664 · Heart Failure
  14. Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies.
    Schaefer F, Montini G, Kang HG, et al. · Trials · 2024 · Derived
    PubMed: PMID 38509517 · NCT05196035 (FIONA) · Renal Insufficiency, Chronic
  15. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
    Sarafidis P, Agarwal R, Pitt B, et al. · Clin J Am Soc Nephrol · 2024 · Derived
    PubMed: PMID 36927680 · NCT02545049 (FIGARO-DKD) · Diabetes Mellitus, Type 2
  16. Experimental Designs for Multicomponent Interventions in Kidney and Cardiometabolic Diseases.
    Rossing P · J Am Soc Nephrol · 2024 · Derived
    PubMed: PMID 39078403 · NCT06082063 (Steno1) · Heart Failure
  17. Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis.
    Rosas SE, Ruilope LM, Anker SD, et al. · Kidney Med · 2024 · Derived
    PubMed: PMID 37745646 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  18. The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design: A Trial Protocol.
    Kotwal SS, Perkovic V, Jardine MJ, et al. · JAMA Netw Open · 2024 · Derived
    PubMed: PMID 39661388 · NCT06058585 (CAPTIVATE) · Renal Insufficiency, Chronic
  19. Clinical Trials for Kidney Disease in the Era of Personalized Medicine.
    Heerspink HJL, Kretzler M · J Am Soc Nephrol · 2024 · Derived
    PubMed: PMID 39248631 · NCT06058585 (CAPTIVATE) · Renal Insufficiency, Chronic
  20. Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial.
    Docherty KF, Henderson AD, Jhund PS, et al. · Circulation · 2024 · Derived
    PubMed: PMID 39342512 · NCT04435626 (FINEARTS-HF) · Heart Failure
  21. Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials.
    Bansal S, Canziani MEF, Birne R, et al. · BMJ Open · 2024 · Derived
    PubMed: PMID 38508632 · NCT02545049 (FIGARO-DKD) · Diabetes Mellitus, Type 2
  22. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease.
    Agarwal R, Pitt B, Palmer BF, et al. · Clin Kidney J · 2024 · Derived
    PubMed: PMID 36864892 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  23. Imaging in Heart Failure with Preserved Ejection Fraction: A Multimodality Imaging Point of View.
    Ünlü S, Özden Ö, Çelik A, et al. · Card Fail Rev · 2024 · Background
    PubMed: PMID 37387734 · NCT07270367 (FINE-MECH) · Heart Failure

2023 (16 papers)

  1. Characteristics of patients with chronic kidney disease and Type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study.
    Vizcaya D, Kovesdy CP, Reyes A, et al. · J Comp Eff Res · 2023 · Derived
    PubMed: PMID 37387399 · NCT05703880 (FIRST-2) · Renal Insufficiency, Chronic
  2. Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR).
    Tanaka A, Shibata H, Imai T, et al. · Cardiovasc Diabetol · 2023 · Derived
    PubMed: PMID 37525257 · NCT05887817 (FIVE-STAR) · Renal Insufficiency, Chronic
  3. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy.
    Rossing P, Filippatos G, Agarwal R, et al. · Kidney Int Rep · 2023 · Derived
    PubMed: PMID 35005312 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  4. Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression.
    Heerspink HJL, Jongs N, Schloemer P, et al. · J Am Soc Nephrol · 2023 · Derived
    PubMed: PMID 37872654 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  5. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial.
    Heerspink HJL, Birkenfeld AL, Cherney DZI, et al. · Diabetes Res Clin Pract · 2023 · Derived
    PubMed: PMID 37805000 · NCT05901831 (FINE-ONE) · Renal Insufficiency, Chronic
  6. Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials.
    Flack JM, Agarwal R, Anker SD, et al. · Kidney Med · 2023 · Derived
    PubMed: PMID 38046911 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  7. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.
    Filippatos G, Anker SD, August P, et al. · Eur Heart J Cardiovasc Pharmacother · 2023 · Derived
    PubMed: PMID 36639130 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  8. Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice.
    Desai NR, Navaneethan SD, Nicholas SB, et al. · J Diabetes Complications · 2023 · Derived
    PubMed: PMID 36857997 · NCT05348733 · Renal Insufficiency, Chronic
  9. Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
    Agarwal R, Tu W, Farjat AE, et al. · Ann Intern Med · 2023 · Derived
    PubMed: PMID 38048573 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  10. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes.
    Agarwal R, Ruilope LM, Ruiz-Hurtado G, et al. · J Hypertens · 2023 · Derived
    PubMed: PMID 36583355 · NCT01874431 (ARTS-DN) · Diabetic Nephropathies
  11. Longitudinal Study of Left Ventricular Mass Index Trajectories and Risk of Mortality in Hypertension: A Cohort Study.
    Zhou D, Huang Y, Cai A, et al. · J Am Heart Assoc · 2023 · Background
    PubMed: PMID 37119065 · NCT07270367 (FINE-MECH) · Heart Failure
  12. Relationship between diffuse fibrosis assessed by CMR and depressed myocardial strain in different stages of heart failure.
    Zhang Y, Zhang X, Wang Y, et al. · Eur J Radiol · 2023 · Background
    PubMed: PMID 37156180 · NCT07270367 (FINE-MECH) · Heart Failure
  13. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.
    Ruilope LM, Pitt B, Anker SD, et al. · Nephrol Dial Transplant · 2023 · Background
    PubMed: PMID 35451488 · NCT06835322 · Proteinuria
  14. Cardiac MRI: State of the Art.
    Rajiah PS, François CJ, Leiner T, et al. · Radiology · 2023 · Background
    PubMed: PMID 37039684 · NCT07270367 (FINE-MECH) · Heart Failure
  15. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).
    Mancia G, Kreutz R, Brunström M, et al. · J Hypertens · 2023 · Background
    PubMed: PMID 37345492 · NCT06457074 · Hyperaldosteronism
  16. Effect of etelcalcetide versus alfacalcidol on left ventricular function and feature-tracking cardiac magnetic resonance imaging in hemodialysis-a post-hoc analysis of a randomized, controlled trial.
    Dörr K, Kammerlander A, Lauriero F, et al. · J Cardiovasc Magn Reson · 2023 · Background
    PubMed: PMID 37932788 · NCT07270367 (FINE-MECH) · Heart Failure

2022 (18 papers)

  1. Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome.
    Zhang Y, Böckhaus J, Wang F, et al. · Pediatr Nephrol · 2022 · Trial result
    PubMed: PMID 33772369 · NCT02378805 (Alport-XXL) · Hematuria, Benign Familial
  2. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
    Filippatos G, Anker SD, Agarwal R, et al. · Circulation · 2022 · Trial result
    PubMed: PMID 34775784 · NCT07351864 (FIN-SGLT2-HF) · Heart Failure
  3. Lifelong effect of therapy in young patients with the COL4A5 Alport missense variant p.(Gly624Asp): a prospective cohort study.
    Boeckhaus J, Hoefele J, Riedhammer KM, et al. · Nephrol Dial Transplant · 2022 · Trial result
    PubMed: PMID 35022790 · NCT02378805 (Alport-XXL) · Hematuria, Benign Familial
  4. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes.
    Ruilope LM, Agarwal R, Anker SD, et al. · Hypertension · 2022 · Derived
    PubMed: PMID 36252131 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  5. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
    Rossing P, Burgess E, Agarwal R, et al. · Diabetes Care · 2022 · Derived
    PubMed: PMID 35061867 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  6. Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
    Pitt B, Agarwal R, Anker SD, et al. · JAMA Netw Open · 2022 · Derived
    PubMed: PMID 36287567 · NCT02545049 (FIGARO-DKD) · Diabetes Mellitus, Type 2
  7. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
    Filippatos G, Anker SD, Pitt B, et al. · JACC Heart Fail · 2022 · Derived
    PubMed: PMID 36328655 · NCT02545049 (FIGARO-DKD) · Diabetes Mellitus, Type 2
  8. Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease.
    Filippatos G, Anker SD, Pitt B, et al. · Eur Heart J Cardiovasc Pharmacother · 2022 · Derived
    PubMed: PMID 36251465 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  9. Mineralcorticoid receptor blockers in chronic kidney disease.
    Erraez S, López-Mesa M, Gómez-Fernández P, et al. · Nefrologia (Engl Ed) · 2022 · Derived
    PubMed: PMID 33358451 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  10. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
    Agarwal R, Anker SD, Filippatos G, et al. · Nephrol Dial Transplant · 2022 · Derived
    PubMed: PMID 34850173 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  11. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
    Agarwal R, Anker SD, Bakris G, et al. · Nephrol Dial Transplant · 2022 · Derived
    PubMed: PMID 33280027 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  12. Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging.
    Smiseth OA, Morris DA, Cardim N, et al. · Eur Heart J Cardiovasc Imaging · 2022 · Background
    PubMed: PMID 34729586 · NCT07270367 (FINE-MECH) · Heart Failure
  13. Characteristics of Heart Failure With Preserved Ejection Fraction Across the Range of Left Ventricular Ejection Fraction.
    Rosch S, Kresoja KP, Besler C, et al. · Circulation · 2022 · Background
    PubMed: PMID 35862208 · NCT07270367 (FINE-MECH) · Heart Failure
  14. Left ventricular mass regression, all-cause and cardiovascular mortality in chronic kidney disease: a meta-analysis.
    Maki KC, Wilcox ML, Dicklin MR, et al. · BMC Nephrol · 2022 · Background
    PubMed: PMID 35034619 · NCT07270367 (FINE-MECH) · Heart Failure
  15. Changes in the Spectrum of Kidney Diseases: An Analysis of 40,759 Biopsy-Proven Cases from 2003 to 2014 in China.
    Hou JH, Zhu HX, Zhou ML, et al. · Kidney Dis (Basel) · 2022 · Background
    PubMed: PMID 29594138 · NCT06835322 · Proteinuria
  16. Multimodality Imaging Assessment of Myocardial Fibrosis.
    Gupta S, Ge Y, Singh A, et al. · JACC Cardiovasc Imaging · 2022 · Background
    PubMed: PMID 34023250 · NCT07270367 (FINE-MECH) · Heart Failure
  17. Aldosterone as a Mediator of Cardiovascular Damage.
    Buffolo F, Tetti M, Mulatero P, et al. · Hypertension · 2022 · Background
    PubMed: PMID 35766038 · NCT07270367 (FINE-MECH) · Heart Failure
  18. Cardiovascular magnetic resonance phenotyping of heart failure with mildly reduced ejection fraction.
    Brown LAE, Wahab A, Ikongo E, et al. · Eur Heart J Cardiovasc Imaging · 2022 · Background
    PubMed: PMID 36285884 · NCT07270367 (FINE-MECH) · Heart Failure

2021 (18 papers)

  1. Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease.
    Snelder N, Heinig R, Drenth HJ, et al. · Clin Pharmacokinet · 2021 · Trial result
    PubMed: PMID 31583611 · NCT01874431 (ARTS-DN) · Diabetic Nephropathies
  2. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
    Pitt B, Filippatos G, Agarwal R, et al. · N Engl J Med · 2021 · Trial result
    PubMed: PMID 34449181 · NCT02545049 (FIGARO-DKD) · Diabetes Mellitus, Type 2
  3. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
    Filippatos G, Anker SD, Agarwal R, et al. · Circulation · 2021 · Trial result
    PubMed: PMID 33198491 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  4. Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Hereditary Podocytopathies, Alport Syndrome, and FSGS: A Case Series to Better Plan a Large-Scale Study.
    Boeckhaus J, Gross O · Cells · 2021 · Trial result
    PubMed: PMID 34359984 · NCT02378805 (Alport-XXL) · Hematuria, Benign Familial
  5. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
    Filippatos G, Bakris GL, Pitt B, et al. · J Am Coll Cardiol · 2021 · Derived
    PubMed: PMID 34015478 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  6. Death after Kidney Transplantation: An Analysis by Era and Time Post-Transplant.
    Ying T, Shi B, Kelly PJ, et al. · J Am Soc Nephrol · 2021 · Background
    PubMed: PMID 32908001 · NCT06059664 · Heart Failure
  7. Myocardial adipose deposition and the development of heart failure with preserved ejection fraction.
    Wu CK, Lee JK, Hsu JC, et al. · Eur J Heart Fail · 2021 · Background
    PubMed: PMID 31696627 · NCT07442448 (FINE-REMODEL) · Heart Failure
  8. Clinical trial recommendations for potential Alport syndrome therapies.
    Weinstock BA, Feldman DL, Fornoni A, et al. · Kidney Int · 2021 · Background
    PubMed: PMID 32386680 · NCT02378805 (Alport-XXL) · Hematuria, Benign Familial
  9. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
    Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. · J Am Coll Cardiol · 2021 · Background
    PubMed: PMID 33197559 · NCT07270367 (FINE-MECH) · Heart Failure
  10. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension.
    Mulatero P, Monticone S, Deinum J, et al. · J Hypertens · 2021 · Background
    PubMed: PMID 32890264 · NCT06457074 · Hyperaldosteronism
  11. Cardiovascular Magnetic Resonance Imaging and Heart Failure.
    Liu C, Ferrari VA, Han Y, et al. · Curr Cardiol Rep · 2021 · Background
    PubMed: PMID 33686516 · NCT07270367 (FINE-MECH) · Heart Failure
  12. Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020.
    Kashtan CE, Gross O · Pediatr Nephrol · 2021 · Background
    PubMed: PMID 33159213 · NCT02378805 (Alport-XXL) · Hematuria, Benign Familial
  13. Myocardial Tissue Characterization and Fibrosis by Imaging.
    Karamitsos TD, Arvanitaki A, Karvounis H, et al. · JACC Cardiovasc Imaging · 2021 · Background
    PubMed: PMID 31542534 · NCT07270367 (FINE-MECH) · Heart Failure
  14. OPTN/SRTR 2019 Annual Data Report: Kidney.
    Hart A, Lentine KL, Smith JM, et al. · Am J Transplant · 2021 · Background
    PubMed: PMID 33595191 · NCT06059664 · Heart Failure
  15. Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction.
    Gehlken C, Screever EM, Suthahar N, et al. · ESC Heart Fail · 2021 · Background
    PubMed: PMID 34085774 · NCT07270367 (FINE-MECH) · Heart Failure
  16. Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction.
    Garg P, Assadi H, Jones R, et al. · Sci Rep · 2021 · Background
    PubMed: PMID 33436786 · NCT07270367 (FINE-MECH) · Heart Failure
  17. Cardiac MRI for the prognostication of heart failure with preserved ejection fraction: A systematic review and meta-analysis.
    Assadi H, Jones R, Swift AJ, et al. · Magn Reson Imaging · 2021 · Background
    PubMed: PMID 33221422 · NCT07270367 (FINE-MECH) · Heart Failure
  18. Glomerulonephritis Histopathological Pattern Change.
    AlYousef A, AlSahow A, AlHelal B, et al. · BMC Nephrol · 2021 · Background
    PubMed: PMID 32423387 · NCT06835322 · Proteinuria

2020 (14 papers)

  1. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
    Ruilope LM, Agarwal R, Anker SD, et al. · Am J Nephrol · 2020 · Trial result
    PubMed: PMID 31665733 · NCT02545049 (FIGARO-DKD) · Diabetes Mellitus, Type 2
  2. Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment.
    Heinig R, Lambelet M, Nagelschmitz J, et al. · Eur J Drug Metab Pharmacokinet · 2020 · Trial result
    PubMed: PMID 30825073 · NCT04881994 · Diabetic Nephropathies
  3. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
    Chung EY, Ruospo M, Natale P, et al. · Cochrane Database Syst Rev · 2020 · Trial result
    PubMed: PMID 33107592 · NCT01874431 (ARTS-DN) · Diabetic Nephropathies
  4. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
    Bakris GL, Agarwal R, Anker SD, et al. · N Engl J Med · 2020 · Trial result
    PubMed: PMID 33264825 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  5. Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis.
    Wang Y, Zhou R, Lu C, et al. · J Am Heart Assoc · 2020 · Background
    PubMed: PMID 31240976 · NCT07270367 (FINE-MECH) · Heart Failure
  6. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Verma S, Mazer CD, Yan AT, et al. · Circulation · 2020 · Background
    PubMed: PMID 31434508 · NCT07270367 (FINE-MECH) · Heart Failure
  7. Diagnosis of Primary Aldosteronism by Seated Saline Suppression Test-Variability Between Immunoassay and HPLC-MS/MS.
    Thuzar M, Young K, Ahmed AH, et al. · J Clin Endocrinol Metab · 2020 · Background
    PubMed: PMID 31676899 · NCT06457074 · Hyperaldosteronism
  8. Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies.
    Rangaswami J, Mathew RO, Parasuraman R, et al. · Nephrol Dial Transplant · 2020 · Background
    PubMed: PMID 30984976 · NCT06059664 · Heart Failure
  9. Left Ventricular Mass at MRI and Long-term Risk of Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis (MESA).
    Kawel-Boehm N, Kronmal R, Eng J, et al. · Radiology · 2020 · Background
    PubMed: PMID 31453766 · NCT07270367 (FINE-MECH) · Heart Failure
  10. Contemporary Application of Cardiovascular Magnetic Resonance Imaging.
    Han Y, Chen Y, Ferrari VA, et al. · Annu Rev Med · 2020 · Background
    PubMed: PMID 31986088 · NCT07270367 (FINE-MECH) · Heart Failure
  11. Late Graft Loss After Kidney Transplantation: Is "Death With Function" Really Death With a Functioning Allograft?
    Gaston RS, Fieberg A, Helgeson ES, et al. · Transplantation · 2020 · Background
    PubMed: PMID 31568212 · NCT06059664 · Heart Failure
  12. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.
    Barrera-Chimal J, Girerd S, Jaisser F, et al. · Kidney Int · 2020 · Background
    PubMed: PMID 31133455 · NCT06835322 · Proteinuria
  13. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
    Bakris GL, Agarwal R, Anker SD, et al. · Am J Nephrol · 2020 · Background
    PubMed: PMID 31655812 · NCT02540993 (FIDELIO-DKD) · Renal Insufficiency, Chronic
  14. Inappropriate Left Ventricular Mass and Cardiovascular Disease Events and Mortality in Blacks: The Jackson Heart Study.
    Anstey DE, Tanner RM, Booth JN, et al. · J Am Heart Assoc · 2020 · Background
    PubMed: PMID 31407619 · NCT07270367 (FINE-MECH) · Heart Failure

2019 (8 papers)

  1. Kidney Injury by Variants in the COL4A5 Gene Aggravated by Polymorphisms in Slit Diaphragm Genes Causes Focal Segmental Glomerulosclerosis.
    Frese J, Kettwig M, Zappel H, et al. · Int J Mol Sci · 2019 · Trial result
    PubMed: PMID 30691124 · NCT02378805 (Alport-XXL) · Hematuria, Benign Familial
  2. Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome.
    Schelbert EB, Fridman Y, Wong TC, et al. · JAMA Cardiol · 2019 · Background
    PubMed: PMID 28768311 · NCT07270367 (FINE-MECH) · Heart Failure
  3. Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association.
    Muntner P, Shimbo D, Carey RM, et al. · Hypertension · 2019 · Background
    PubMed: PMID 30827125 · NCT06457074 · Hyperaldosteronism
  4. De Novo Heart Failure After Kidney Transplantation: Trends in Incidence and Outcomes.
    Lenihan CR, Liu S, Deswal A, et al. · Am J Kidney Dis · 2019 · Background
    PubMed: PMID 29605378 · NCT06059664 · Heart Failure
  5. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity.
    Grune J, Beyhoff N, Smeir E, et al. · Hypertension · 2019 · Background
    PubMed: PMID 29437893 · NCT06835322 · Proteinuria
  6. Late graft failure after kidney transplantation as the consequence of late versus early events.
    Gaston RS, Fieberg A, Hunsicker L, et al. · Am J Transplant · 2019 · Background
    PubMed: PMID 29139625 · NCT06059664 · Heart Failure
  7. Progression of Hypertrophy and Myocardial Fibrosis in Aortic Stenosis: A Multicenter Cardiac Magnetic Resonance Study.
    Everett RJ, Tastet L, Clavel MA, et al. · Circ Cardiovasc Imaging · 2019 · Background
    PubMed: PMID 29914867 · NCT07270367 (FINE-MECH) · Heart Failure
  8. Trends in the Causes of Death among Kidney Transplant Recipients in the United States (1996-2014).
    Awan AA, Niu J, Pan JS, et al. · Am J Nephrol · 2019 · Background
    PubMed: PMID 30472701 · NCT06059664 · Heart Failure

2018 (4 papers)

  1. Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations.
    Stock J, Kuenanz J, Glonke N, et al. · Pediatr Nephrol · 2018 · Trial result
    PubMed: PMID 27402170 · NCT02378805 (Alport-XXL) · Hematuria, Benign Familial
  2. Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals With Renal Impairment.
    Heinig R, Kimmeskamp-Kirschbaum N, Halabi A, et al. · Clin Pharmacol Drug Dev · 2018 · Trial result
    PubMed: PMID 27431783 · NCT04908436 · Renal Insufficiency, Chronic
  3. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
    Filippatos G, Anker SD, Böhm M, et al. · Eur Heart J · 2018 · Trial result
    PubMed: PMID 27130705 · NCT01807221 (ARTS-HF) · Heart Failure
  4. Albuminuria and posttransplant chronic kidney disease stage predict transplant outcomes.
    Lam NN, Tonelli M, Lentine KL, et al. · Kidney Int · 2018 · Background
    PubMed: PMID 28366228 · NCT06059664 · Heart Failure

2017 (4 papers)

  1. Diagnosis and management of primary aldosteronism.
    Vilela LAP, Almeida MQ · Arch Endocrinol Metab · 2017 · Background
    PubMed: PMID 28699986 · NCT06457074 · Hyperaldosteronism
  2. Confirmatory Tests for the Diagnosis of Primary Aldosteronism: A Prospective Diagnostic Accuracy Study.
    Song Y, Yang S, He W, et al. · Hypertension · 2017 · Background
    PubMed: PMID 29158354 · NCT06457074 · Hyperaldosteronism
  3. Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review.
    Haaf P, Garg P, Messroghli DR, et al. · J Cardiovasc Magn Reson · 2017 · Background
    PubMed: PMID 27899132 · NCT07270367 (FINE-MECH) · Heart Failure
  4. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.
    Funder JW, Carey RM, Mantero F, et al. · J Clin Endocrinol Metab · 2017 · Background
    PubMed: PMID 26934393 · NCT06457074 · Hyperaldosteronism

2016 (2 papers)

  1. Role of cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology.
    von Knobelsdorff-Brenkenhoff F, Schulz-Menger J · J Cardiovasc Magn Reson · 2016 · Background
    PubMed: PMID 26800662 · NCT07270367 (FINE-MECH) · Heart Failure
  2. Laboratory challenges in primary aldosteronism screening and diagnosis.
    Rehan M, Raizman JE, Cavalier E, et al. · Clin Biochem · 2016 · Background
    PubMed: PMID 25619896 · NCT06457074 · Hyperaldosteronism

2015 (5 papers)

  1. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
    Pitt B, Anker SD, Böhm M, et al. · Eur J Heart Fail · 2015 · Trial result
    PubMed: PMID 25678098 · NCT01807221 (ARTS-HF) · Heart Failure
  2. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
    Bakris GL, Agarwal R, Chan JC, et al. · JAMA · 2015 · Trial result
    PubMed: PMID 26325557 · NCT01874431 (ARTS-DN) · Diabetic Nephropathies
  3. CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF.
    Su MY, Lin LY, Tseng YH, et al. · JACC Cardiovasc Imaging · 2015 · Background
    PubMed: PMID 25240451 · NCT07442448 (FINE-REMODEL) · Heart Failure
  4. Left ventricular mass and the risk of sudden cardiac death: a population-based study.
    Laukkanen JA, Khan H, Kurl S, et al. · J Am Heart Assoc · 2015 · Background
    PubMed: PMID 25376188 · NCT07270367 (FINE-MECH) · Heart Failure
  5. Cardiac MRI: a central prognostic tool in myocardial fibrosis.
    Ambale-Venkatesh B, Lima JA · Nat Rev Cardiol · 2015 · Background
    PubMed: PMID 25348690 · NCT07270367 (FINE-MECH) · Heart Failure

2014 (1 paper)

  1. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.
    Pitt B, Kober L, Ponikowski P, et al. · Eur Heart J · 2014 · Background
    PubMed: PMID 23713082 · NCT06457074 · Hyperaldosteronism

2013 (3 papers)

  1. Outcomes of male patients with Alport syndrome undergoing renal replacement therapy.
    Temme J, Kramer A, Jager KJ, et al. · Clin J Am Soc Nephrol · 2013 · Trial result
    PubMed: PMID 22997344 · NCT02378805 (Alport-XXL) · Hematuria, Benign Familial
  2. Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study.
    Morales JM, Marcén R, del Castillo D, et al. · Nephrol Dial Transplant · 2013 · Background
    PubMed: PMID 23258810 · NCT06059664 · Heart Failure
  3. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade.
    Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, et al. · Heart · 2013 · Background
    PubMed: PMID 23343682 · NCT07270367 (FINE-MECH) · Heart Failure

2012 (2 papers)

  1. Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations.
    Temme J, Peters F, Lange K, et al. · Kidney Int · 2012 · Trial result
    PubMed: PMID 22237748 · NCT02378805 (Alport-XXL) · Hematuria, Benign Familial
  2. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy.
    Gross O, Licht C, Anders HJ, et al. · Kidney Int · 2012 · Trial result
    PubMed: PMID 22166847 · NCT02378805 (Alport-XXL) · Hematuria, Benign Familial

2011 (2 papers)

  1. Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry.
    Gaasch WH, Zile MR · J Am Coll Cardiol · 2011 · Background
    PubMed: PMID 21996383 · NCT07270367 (FINE-MECH) · Heart Failure
  2. LV reverse remodeling imparted by aortic valve replacement for severe aortic stenosis; is it durable? A cardiovascular MRI study sponsored by the American Heart Association.
    Biederman RW, Magovern JA, Grant SB, et al. · J Cardiothorac Surg · 2011 · Background
    PubMed: PMID 21492429 · NCT07270367 (FINE-MECH) · Heart Failure

2010 (1 paper)

  1. Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure.
    Vizzardi E, D'Aloia A, Giubbini R, et al. · Am J Cardiol · 2010 · Background
    PubMed: PMID 21029826 · NCT07270367 (FINE-MECH) · Heart Failure

2009 (2 papers)

  1. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study.
    Verma A, Meris A, Skali H, et al. · JACC Cardiovasc Imaging · 2009 · Background
    PubMed: PMID 19356485 · NCT07270367 (FINE-MECH) · Heart Failure
  2. Proteinuria in kidney transplant recipients: prevalence, prognosis, and evidence-based management.
    Knoll GA · Am J Kidney Dis · 2009 · Background
    PubMed: PMID 19726115 · NCT06059664 · Heart Failure

2008 (2 papers)

  1. Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure.
    Kasama S, Toyama T, Sumino H, et al. · J Nucl Med · 2008 · Background
    PubMed: PMID 18006623 · NCT07270367 (FINE-MECH) · Heart Failure
  2. Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study.
    de Simone G, Gottdiener JS, Chinali M, et al. · Eur Heart J · 2008 · Background
    PubMed: PMID 18204091 · NCT07270367 (FINE-MECH) · Heart Failure

2007 (2 papers)

  1. Risk factors for rising creatinine in renal allografts with 1 and 3 yr survival.
    Paraskevas S, Kandaswamy R, Humar A, et al. · Clin Transplant · 2007 · Background
    PubMed: PMID 17100713 · NCT06059664 · Heart Failure
  2. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure.
    Chan AK, Sanderson JE, Wang T, et al. · J Am Coll Cardiol · 2007 · Background
    PubMed: PMID 17692742 · NCT07270367 (FINE-MECH) · Heart Failure

2005 (2 papers)

  1. Aldosterone directly stimulates cardiac myocyte hypertrophy.
    Okoshi MP, Yan X, Okoshi K, et al. · J Card Fail · 2005 · Background
    PubMed: PMID 15599842 · NCT07270367 (FINE-MECH) · Heart Failure
  2. The 45-year story of the development of an anti-aldosterone more specific than spironolactone.
    Ménard J · Mol Cell Endocrinol · 2005 · Background
    PubMed: PMID 15134800 · NCT06457074 · Hyperaldosteronism

2004 (2 papers)

  1. The burden of chronic kidney disease in renal transplant recipients.
    Karthikeyan V, Karpinski J, Nair RC, et al. · Am J Transplant · 2004 · Background
    PubMed: PMID 14974949 · NCT06059664 · Heart Failure
  2. Prognostic significance of left ventricular mass change during treatment of hypertension.
    Devereux RB, Wachtell K, Gerdts E, et al. · JAMA · 2004 · Background
    PubMed: PMID 15547162 · NCT07270367 (FINE-MECH) · Heart Failure

2003 (2 papers)

  1. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation.
    Meier-Kriesche HU, Baliga R, Kaplan B, et al. · Transplantation · 2003 · Background
    PubMed: PMID 12717218 · NCT06059664 · Heart Failure
  2. Five preventable causes of kidney graft loss in the 1990s: a single-center analysis.
    Matas AJ, Humar A, Gillingham KJ, et al. · Kidney Int · 2003 · Background
    PubMed: PMID 12110036 · NCT06059664 · Heart Failure

2002 (2 papers)

  1. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism.
    Rossi GP, Di Bello V, Ganzaroli C, et al. · Hypertension · 2002 · Background
    PubMed: PMID 12105133 · NCT07270367 (FINE-MECH) · Heart Failure
  2. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure.
    Cicoira M, Zanolla L, Rossi A, et al. · J Am Coll Cardiol · 2002 · Background
    PubMed: PMID 12106936 · NCT07270367 (FINE-MECH) · Heart Failure

2000 (1 paper)

  1. Cardiac aldosterone production and ventricular remodeling.
    Delcayre C, Silvestre JS, Garnier A, et al. · Kidney Int · 2000 · Background
    PubMed: PMID 10760065 · NCT07270367 (FINE-MECH) · Heart Failure

1999 (1 paper)

  1. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.
    Wolfe RA, Ashby VB, Milford EL, et al. · N Engl J Med · 1999 · Background
    PubMed: PMID 10580071 · NCT06059664 · Heart Failure

1997 (1 paper)

  1. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension.
    Tanabe A, Naruse M, Naruse K, et al. · Hypertens Res · 1997 · Background
    PubMed: PMID 9220271 · NCT07270367 (FINE-MECH) · Heart Failure

1993 (1 paper)

  1. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis.
    Brilla CG, Weber KT · J Lab Clin Med · 1993 · Background
    PubMed: PMID 1453111 · NCT07270367 (FINE-MECH) · Heart Failure

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).